Dipeptidyl peptidase 3-positive circulatory shock: from targetable intensive care unit endotype to Horizon Europe precision-therapy trial

Mahir Karakas, Karolina Ziolkowska, Olga Kovalenko, Serhiy Zemskov, Anna V Blagaia, Tanja Zeller, Anja M Boos

Open source

DOI
10.1093/ejhf/xuag328
Published
2026-11-02
Container
European Journal of Heart Failure
Publisher
Oxford University Press (OUP)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/ejhf/xuag328,
  title = {Dipeptidyl peptidase 3-positive circulatory shock: from targetable intensive care unit endotype to Horizon Europe precision-therapy trial},
  author = {Mahir Karakas and Karolina Ziolkowska and Olga Kovalenko and Serhiy Zemskov and Anna V Blagaia and Tanja Zeller and Anja M Boos},
  year = {2026},
  journal = {European Journal of Heart Failure},
  doi = {10.1093/ejhf/xuag328},
  url = {https://doi.org/10.1093/ejhf/xuag328}
}

RIS

TY  - JOUR
TI  - Dipeptidyl peptidase 3-positive circulatory shock: from targetable intensive care unit endotype to Horizon Europe precision-therapy trial
AU  - Mahir Karakas
AU  - Karolina Ziolkowska
AU  - Olga Kovalenko
AU  - Serhiy Zemskov
AU  - Anna V Blagaia
AU  - Tanja Zeller
AU  - Anja M Boos
PY  - 2026
JO  - European Journal of Heart Failure
DO  - 10.1093/ejhf/xuag328
UR  - https://doi.org/10.1093/ejhf/xuag328
ER  - 

APA

Karakas, M., Ziolkowska, K., Kovalenko, O., Zemskov, S., Blagaia, A. V., Zeller, T., & Boos, A. M. (2026). Dipeptidyl peptidase 3-positive circulatory shock: from targetable intensive care unit endotype to Horizon Europe precision-therapy trial. European Journal of Heart Failure. https://doi.org/10.1093/ejhf/xuag328

Source records